Loading...
Last update:  May 26, 2023
08:28 +1GMT

Allergenic Molecule  Act d 1Homo sapiens  
Epidemiology from Literature
CohortYearCountryTestSubjectsPositive (%)Bibliography
1.5 - Atopic Dermatitis, Diagnosed2014NetherlandsIgE21111.40020140331, Rockmann H
3.2.1 - Source Sensitized (IgE)2013ItalyIgE28439.44020130420, Palazzo P
1.5 - Atopic Dermatitis, Diagnosed2013GermanyIgE1404.29020130111, Ott H
1.3 - Rhinitis, Diagnosed2013BrazilIgE1010.90020130912, Lacerda Araujo LM
5.2.1 - Source Exposed (Symptoms, SPT)2013ItalyIgE498.16020130420, Palazzo P
5.2.1 - Source Exposed (Symptoms, SPT)2013ItalyIgE (IB)4981.63020130420, Palazzo P
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2013ItalyIgE3619.44020130420, Palazzo P
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2013ItalySPT3636.11020130420, Palazzo P
1.11 - Esophagitis, Diagnosed2013SwitzerlandIgE352.86020130605, Simon D
6.2 - General Population (Adults)2012SwedenIgE3710.00020120528, Patelis A
1.8 - Fruit Allergy2012SpainIgE21221.00020120912, Palacin A
5.1.1 - Source Exposed (Symptoms)2012France / Italy / Netherlands / Switzerland / United KingdomIgE18111.00020121112, Le TM
1.9 - Pollen Allergy2012SpainIgE1177.00020120912, Palacin A
5.3.1 - Source Exposed (Symptoms, IgE)2012BelgiumIgE998.08020110223, De Knop KJ
1.2.1 - Asthma, Diagnosed (Adults)2012SwedenIgE960.00020120528, Patelis A
5.1.1 - Source Exposed (Symptoms)2012Bulgaria / Czech Republic / Lithuania / PolandIgE5618.00020121112, Le TM
5.1.1 - Source Exposed (Symptoms)2012Greece / SpainIgE4516.00020121112, Le TM
5.1.1 - Source Exposed (Symptoms)2012IcelandIgE2932.00020121112, Le TM
10.1 - Normal Control2012BelgiumIgE270.00020110223, De Knop KJ
3.2.1 - Source Sensitized (IgE)2011ItalyIgE83540.00020110211, DAvino R
4.1.6 - Heterologous Source Sensitized (High IgE)2011ItalyIgE2149.81020110211, DAvino R
4.1.2 - Heterologous Source Sensitized (Symptoms, SPT)2011ChinaIgE1000.00020111214, Zheng YW
4.1.6 - Heterologous Source Sensitized (High IgE)2011AustriaIgE603.33020110211, DAvino R
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2010Italy / Austria / Switzerland / NetherlandsIgE23728.27020101118, Bublin M
3.1.4 - Source Sensitized (SPT, IgE)2010Italy / Austria / Switzerland / NetherlandsIgE1985.05020101118, Bublin M
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2010SwitzerlandIgE3020.00020100111, Bublin M
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2010ItalyIgE1154.54020100909, Bernardi ML
4.1.7 - Heterologous Source Sensitized (Symptoms, SPT, IgE)2009BelgiumIgE372.70020090826, Ebo DG
10.1 - Normal Control2009BelgiumIgE260.00020091121, Ebo DG
4.1.4 - Heterologous Source Sensitized (Symptoms, IgE)2009BelgiumIgE224.55020091121, Ebo DG
4.1.5 - Heterologous Source Sensitized (IgE)2009BelgiumIgE2015.00020091121, Ebo DG
1.5 - Atopic Dermatitis, Diagnosed2009GermanyIgE200.00020091005, Ott H
5.2.1 - Source Exposed (Symptoms, SPT)2008SpainIgE9259.78020080119, Palacin A
5.2.1 - Source Exposed (Symptoms, SPT)2008SpainSPT2572.00020080119, Palacin A
5.4.1 - Source Exposed (Symptoms, SPT, IgE)2007United KingdomIgE200.00020070720, Lucas JS
5.1.1 - Source Exposed (Symptoms)2004ItalyIgE3447.10020041113, Bublin M
5.1.1 - Source Exposed (Symptoms)2004AustriaIgE3187.10020041113, Bublin M
5.1.1 - Source Exposed (Symptoms)2004NetherlandsIgE1080.00020041113, Bublin M
Developed by
Panservice